bene-Arzneimittel

Munich, Germany· Est. 1978

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

bene-Arzneimittel is a well-established, private German pharmaceutical company with a 70+ year legacy originating from its founder's synthesis of sodium pentosan polysulfate (NaPPS). Its business is built on a dual foundation: a portfolio of trusted, classic OTC products like ben-u-ron® for pain and fever, and a proprietary platform around the unique active substance NaPPS, which has led to approved prescription drugs. With approximately 120 employees, the company maintains full control over its supply chain through a subsidiary for API manufacturing and emphasizes quality production in Germany, while pursuing international expansion and new product development.

PainFeverRespiratory Tract DiseasesArteriovenous DiseasesEaracheInterstitial Cystitis / Bladder Pain Syndrome

Technology Platform

Proprietary expertise in the synthesis, manufacturing, and development of pharmaceuticals based on sodium pentosan polysulfate (NaPPS), a unique synthetic polysaccharide with anticoagulant and antithrombotic properties. Full vertical integration through subsidiary API manufacturing.

Opportunities

The EU approval for elmiron® provides a first-mover advantage in the treatment of interstitial cystitis, a niche but significant unmet medical need.

International expansion, particularly leveraging the 'Made in Germany' quality brand in emerging markets, offers a clear growth path for both OTC and prescription products.

Further development of the NaPPS platform for new indications could drive long-term innovation.

Risk Factors

Revenue reliance on the mature and competitive OTC analgesic market, particularly the ben-u-ron® brand.

Commercial execution risk associated with launching the specialty product elmiron® in a new therapeutic area.

Geographic concentration in the German market exposes the company to regional pricing and regulatory pressures.

Competitive Landscape

In OTC analgesics, bene competes with global consumer health giants (Bayer, GSK, Johnson & Johnson) and generic manufacturers, competing on brand trust and quality. In the interstitial cystitis space, elmiron® faces competition from off-label treatments, generics (in markets where it is not patented), and any future novel therapies, but currently holds a unique position as the first EU-approved therapy.